Stockreport

Alto Neuroscience Starts Phase 2b Trial of ALTO-207 in Treatment-Resistant Depression [Yahoo! Finance]

Alto Neuroscience, Inc.  (ANRO) 
PDF Alto Neuroscience (ANRO) said Tuesday it has initiated a Phase 2b trial of its candidate ALTO-207 in [Read more]